Ana Ruth Mejia-Elizondo

Dr. Ana Ruth Mejia-Elizondo

Posgrado Pediatría/Neonatología, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
YLYamile Lopez
Yamile Lopez
VLVictoria Lima-Rogel
Victoria Lima-Rogel
RMRupasri Mandal
Rupasri Mandal
JZJiamin Zheng
Jiamin Zheng
LZLun Zhang
Lun Zhang
David Scott WishartDavid Scott Wishart
David Scott Wishart
Maternal pathological conditions such as infections and chronic diseases, along with unexpected events during labor, can lead to life-threatening perinatal outcomes. These outcomes can have irreversible consequences throughout an individual’s entire life. Urinary metabolomics can provide valuable insights into early physiological adaptations in healthy newborns, as well as metabolic disturbances in premature infants or infants with birth complications. In the present study, we measured 180 metabolites and metabolite ratios in the urine of 13 healthy (hospital-discharged) and 38 critically ill newborns (admitted to the neonatal intensive care unit (NICU)). We used an in-house-developed targeted tandem mass spectrometry (MS/MS)-based metabolomic assay (TMIC Mega) combining liquid chromatography (LC-MS/MS) and flow injection analysis (FIA-MS/MS) to quantitatively analyze up to 26 classes of compounds. Average urinary concentrations (and ranges) for 167 different metabolites from 38 critically ill NICU newborns during their first 24 h of life were determined. Similar sets of urinary values were determined for the 13 healthy newborns. These reference data have been uploaded to the Human Metabolome Database. Urinary concentrations and ranges of 37 metabolites are reported for the first time for newborns. Significant differences were found in the urinary levels of 44 metabolites between healthy newborns and those admitted at the NICU. Metabolites such as acylcarnitines, amino acids and derivatives, biogenic amines, sugars, and organic acids are dysregulated in newborns with bronchopulmonary dysplasia (BPD), asphyxia, or newborns exposed to SARS-CoV-2 during the intrauterine period. Urine can serve as a valuable source of information for understanding metabolic alterations associated with life-threatening perinatal outcomes.

7 January 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
FBFrida S. Boer-Pérez
Frida S. Boer-Pérez
VLVictoria Lima-Rogel
Victoria Lima-Rogel
SRSilvia Romano-Moreno
Silvia Romano-Moreno
AMAna Ruth Mejia-Elizondo
Ana Ruth Mejia-Elizondo
SMSusanna E. Medellín-Garibay
Susanna E. Medellín-Garibay
RMRosa del Carmen Milán-Segovia
Rosa del Carmen Milán-Segovia
Piperacillin-tazobactam is widely used off-label in neonates for the empirical treatment of severe infections, resulting in diverse dosing regimens across clinical settings. This variability, combined with high interindividual differences in renal maturation that impact drug disposition, complicates standardized dosing and emphasizes the need for individualized, evidence-based strategies. This study aimed to develop and evaluate a population pharmacokinetic model of piperacillin in neonates to support optimized initial dosing recommendations. Neonatal patients (postnatal age ≤28 days) admitted to an intensive care unit who received piperacillin-tazobactam (8:1 ratio) at Neofax-recommended doses were included. Plasma concentrations were measured using an ultra-high-performance liquid chromatography with tandem mass spectrometry method. Population pharmacokinetic analysis for piperacillin was performed using nonlinear mixed-effects modeling. A total of 65 blood samples were collected from 25 neonates, both preterm (56%) and full-term. Piperacillin pharmacokinetics was best described by a one-compartment model incorporating body weight-based allometric scaling, postmenstrual age, and serum creatinine as covariates influencing clearance. For a typical neonate in the study (1.76 kg), the estimated clearance was 0.748 L/h (coefficient of variation, 38.3%), and the volume of distribution was 0.866 L (37.7%). Simulations indicated adequate probability of target attainment with current recommendations, but a high proportion of preterm neonates (>75%) were at risk of overexposure (trough piperacillin plasma concentration >50 mg/L). Additional simulations supported individualized initial regimens based on renal maturation and suggested that extended infusions (1−4 h) may improve target attainment for stricter targets and less-susceptible pathogens. This study provides a validated pharmacokinetic model for piperacillin in neonates with severe infections, offering a framework to optimize empiric dosing based on renal function and developmental stage.

1 July 2024 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
FBFrida S. Boer-Pérez
Frida S. Boer-Pérez
VLVictoria Lima-Rogel
Victoria Lima-Rogel
AMAna Ruth Mejia-Elizondo
Ana Ruth Mejia-Elizondo
SMSusanna E. Medellín-Garibay
Susanna E. Medellín-Garibay
ARAna S. Rodríguez-Báez
Ana S. Rodríguez-Báez
SRSilvia Romano-Moreno
Silvia Romano-Moreno